Lv6
2770 积分 2024-09-08 加入
Triple negative breast cancer: approved treatment options and their mechanisms of action
1天前
已完结
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer
29天前
已完结
A single-cell and spatially resolved atlas of human breast cancers
29天前
已完结
Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis
29天前
已完结
Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment
29天前
已完结
SGLT2 inhibitor monotherapy alleviates hyperglycemia in heredity severe insulin resistance syndrome
3个月前
已完结
EGFR-mutant non-small cell lung cancer patients harboring CDK4 amplification show favorable response to afatinib: Two case reports
3个月前
已完结
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
3个月前
已完结
EPIK-B5: A phase III, randomized study of alpelisib (ALP) plus fulvestrant (FUL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) progressing on/after an aromatase inhibitor (AI) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i)
3个月前
已关闭
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
3个月前
已完结
皖公网安备34019202002308
